Swedish biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO: SOBI) on Thursday reported late-breaking data from the phase 3 REDUCE-2 study showing that investigational gout treatment pozdeutinurad (AR882) delivered statistically significant and sustained reductions in serum urate levels for up to 12 months.

The global trial enrolled 811 patients with uncontrolled gout, randomised to receive pozdeutinurad 75mg, pozdeutinurad 50mg or placebo. The study met its primary endpoint, with 69.2% and 56.6% of patients in the 75mg and 50mg groups achieving serum urate levels below 6mg/dL at six months, compared with 8.1% of placebo recipients (both p